BioNexus Gene Lab Corp. Form 8-K Filing

BioNexus Gene Lab Corp. is evaluating a potential expansion into Contract Development and Manufacturing (CDMO) activities through its subsidiary, Chemrex Corporation Sdn. Bhd. This evaluation is part of a broader business rationalization initiative due to challenges in Chemrex's legacy operations and the company's strategic shift towards biotechnology. A governance review of Chemrex, including an assessment of historical matters, is ongoing to enhance oversight and internal controls. As part of this review and to regularize Chemrex's board and management structure, additional directors were appointed to Chemrex's board, and Mr. Matthew L. Barsing was appointed as director and Chairman of the Board of Chemrex. On December 19, 2025, four individuals resigned from their positions as officers and directors of Chemrex. The company is continuing to evaluate the impact of these resignations and potential courses of action.